John M. Pagel, MD, PhD
Dr. John Pagel is an assistant professor of Medicine, in the UW Division of Oncology and an assistant member at the Fred Hutchinson Cancer Research Center. He specializes in stem cell transplantation, leukemia, and lymphoma treatment.
Dr. Pagel’s clinical and research interests focus on the translation of novel immunotherapeutic approaches from the laboratory to patients with leukemias and lymphomas. He has served as an investigator for a number of clinical trials for patients with advanced hematologic malignancies and has been the principal investigator on a series of protocols using high-dose radiolabeled antibody therapy as part of a conditioning regimen for patients undergoing stem cell transplantation at Fred Hutchinson Cancer Research Center.
Dr. Pagel is also involved in laboratory research and his interests include developing improved immunotherapeutic approaches for the targeted delivery of radiotherapy. He has published a number of research papers focusing on radioimmunotherapy of hematologic malignancies in a variety of publications, including Blood, Journal of Clinical Oncology, Cancer Research, Bone Marrow Transplantation, and the Proceedings of the National Academy of Sciences.
He received his medical degree from Boston University School of Medicine and went on to complete his residency in internal medicine at the University of California, San Francisco. Dr. Pagel obtained his PhD in Microbiology and Molecular Genetics as well as his BA in Biology from the University of California.
He subsequently trained as an oncology fellow at the University of Washington, where he currently serves on the faculty.
Dr. Pagel has received numerous awards, including the ASCO Young Investigator Award, Career Development Awards from ASCO and the Lymphoma Research Foundation, and a Damon Runyon Clinical Investigator Award. In addition, Dr. Pagel is a member of several professional societies, including the American Association of Cancer Research, the American Society of Hematology, and the American Association of Clinical Oncology.
John M. Pagel, MD, PhD
Dr. Pagel specializes in stem cell transplantation for leukemia and lymphoma treatment.Patient Care Philosophy:
I strive to establish a foundation of mutual trust and respect with every patient in order to provide the best care possible for each individual patient.
Title
- Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Assistant Professor, Medical Oncology Division, University of Washington School of Medicine
Clinical Expertise
Targeted leukemia therapies - Radiolabeled antibody therapies for high-risk leukemias; Dr. Pagel leads leukemia studies of radioimmunotherapy at the Center as the principal investigator of several human clinical trials. He is working to increase the usefulness of antibody therapy by "pretargeting" radiation directly to the cells. He is also researching nonradioactive chemical partners to antibodies.
Education And Training
- Boston University School of Medicine, 1996
- Residency: University of California. San Francisco Internal Medicine, 1997-1999
- Fellowship: University of Washington Oncology, 1999-2002
- Assistant Member, Clinical Research, Fred Hutchinson Cancer Research Center
- Assistant Professor, UW Medicine, Oncology
More Information
For more information about Dr. John M. Pagel's clinical and research expertise, click here.
Clinical Trials
- Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
- Anti-CD45 Antibody followed by Transplant for AML or MDS (2468)
- CWP232291 for Relapsed or Refractory AML (2513)